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Abstract
Aim: Recurrent implantation failure (RIF) affects 10% of couples undergoing assisted conception, often due
to poor endometrial receptivity. We conducted a systematic review and meta-analysis to evaluate the effec-
tiveness of Intra-venous intralipid (IVI) in improving pregnancy rates in women with history of RIF using.
Methods: We searched MEDLINE, EMBASE, and CENTRAL for any randomized trials evaluating the use
of IVI at the time of embryo transfer in women undergoing assisted conception until September 2020. We
extracted data in duplicate and assessed risk of bias using the Cochrane Risk of Bias tools. We meta-
analyzed data using a random effect model.
Results: We included five randomized trials reporting on 843 women with an overall moderate risk of bias.
All trials used 20% IVI solution at the time of embryo transfer compared to normal saline infusion or no
intervention (routine care). The IVI group had a higher chance of clinical pregnancy (172 vs 119, risk ratio
[RR] 1.55, 95% confidence interval [CI] 1.16–2.07, I2 44.2%) and live birth (132 vs 73, RR 1.83, 95% CI
1.42–2.35, I2 0%) post treatment compared to no intervention. Our findings are limited by the small sample
size and the variations in treatment protocols and population characteristics.
Conclusion: There is limited evidence to support the use of IVI at the time of embryo transfer in women
with the history of RIF. More research is needed before adopting it in clinical practice.
Key words: assisted reproductive technology, immunotherapy, intralipid, recurrent implantation failure,
recurrent pregnancy loss.
Introduction
More and more couples rely on assisted reproductive
technology (ART) to become pregnant worldwide,
with an annually rising numbers of cycles per-
formed.1 Still, optimizing the implantation process
following embryo transfer remains a clinical challenge
with 10% of couples undergoing ART affected by
recurrent implantation failure (RIF).2, 3 RIF, defined as
the repeated implantation failure in spite of the trans-
fer of good quality embryos following ART
treatment,4 continues to be a clinical dilemma contrib-
uting to increased morbidity and anxiety in affected
couples. Several factors are thought to increase the
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risk of RIF such as embryo quality, maternal
thrombophilia, uterine abnormalities, and endocrine
disorders.4, 5 Still, we do not have a comprehensive
understanding of the implantation process despite
extensive research.6
Recently, our increased understanding of the
implantation window characteristics governed by
subtitle yet highly regulated pro- and anti-
inflammatory responses7, 8 highlighted the potential
effect of aberrant immune responses on implantation
and pregnancy outcomes.9 The role of immunother-
apy to regulate the maternal immune system has
received much attention recently, with a presumed
effect in improving endometrial receptivity and the
chances for successful conception.10 Mothers with his-
tory of recurrent pregnancy loss and implantation
failure seem to have an impaired immunological
response driven by an increased activity of uterine
natural killer (uNK), macrophages, and T1 helper cells
elevating cytokine production and cytotoxicity in the
endometrium.11–13 However, effective screening and
diagnostic methods are lacking which limits the pro-
cess of patient and treatment matching. Various
immunological therapies have been evaluated as ART
add-on treatments, but evidence of their value to the
general population remains unclear.14
Intravenous intralipid (IVI), a fat-based emulsion of
soybean oil, glycerine, phospholipids, egg, and poly-
unsaturated fatty acids, has been evaluated in several
trials as a potential intervention to suppress the
maternal immunological response,15, 16 which seems
to be mediated by reduced monocyte endothelial
adhesion and pro-inflammatory cytokine genera-
tion.16 Although its overall mechanistic effect on the
immune system remains unclear, several studies sup-
port its role in downregulating the uNK cell macro-
phages pro-inflammatory mediators especially T1
helper cells.15 This seems to be mediated by the inter-
action between the intralipid fatty acids of and the
uNK cell peroxisome proliferator-activated receptors
which decrease uNK cytotoxicity through reduced
secretion of interferon-γ, demonstrated both in vivo
and in vitro.17, 18
As such, the value and safety of selectively using
IVI in women with the history of RIF to improve
their reproductive outcomes need careful evaluation.
We aimed to examine this hypothesis by syste-
matically reviewing the literature for randomized
trials evaluating the effectiveness of IVI to increase
the chance of successful conception post ART
treatments.
Materials and Methods
We performed this systematic review using a prospec-
tively registered protocol (CRD42019148517) and
reported in accordance with the PRISMA
guidelines.19
Literature search
We searched major electronic databases (MEDLINE,
EMBASE, and Cochrane CENTRAL) for any random-
ized trials meeting our inclusion criteria from incep-
tion until September 2020.
We used the following MeSH search terms and com-
bined them using the Boolean operators AND/OR to
screen for relevant trials (“intralipid,” “pregnancy
outcomes,” “pregnancy,” “biochemical pregnancy,”
“clinical pregnancy,” “ongoing pregnancy,” “live birth,”
“birth,” “pregnancy loss,” “implantation failure,”
“miscarriage,” “reproductive technology,” “ART,”
“assisted reproductive technology,” “IVF,” “in vitro
fertilisation,” “ICSI,” “intracytoplasmic sperm injection,”
and “embryo transfer”). No search filters or language
restrictions were applied. We manually searched the
bibliographies of any relevant articles to identify any
missing studies. We contacted two groups of
authors20, 21 seeking further information before con-
firming eligibility for inclusion in our review.
Study inclusion and data extraction
Two independent reviewers (M.P. Rimmer and
N. Black) completed the study selection and inclusion
process in two stages. Initially, we screened titles and
abstracts to identify potentially relevant trials and
then reviewed the full texts against our inclusion
criteria. We included all randomized trials evaluating
the use of IVI during IVF/ICSI in women with history
of RIF. Any discrepancies were resolved in consensus
with a third reviewer (B.H. Al Wattar). We excluded
non-randomized studies, animal studies, and review
articles. We extracted data in duplicate (M.P. Rimmer
and N. Black) using a piloted electronic data extrac-
tion tool reporting on the number of participants,
inclusion and exclusion criteria, treatment protocols,
clinical pregnancy or implantation rate (defined as
biochemical testing or ultrasound), and live birth or
ongoing pregnancy beyond 12 weeks’ gestation.
Risk of bias
Two reviewers (M.P. Rimmer and N. Black) assessed
the methodological quality of the included RCTs
using the Cochrane risk of bias tool.22 We evaluated
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each study in five domains: randomization and
sequence generation, allocation concealment, blinding
and outcome assessment, completeness of outcome
data, and selective outcome reporting.
Statistical analysis
We conducted a pairwise effectiveness meta-analysis
using a random-effects model and adjusted using
restricted maximum likelihood.23 We reported on
dichotomous outcomes using risk ratio (RR) and 95%
confidence interval (CI). We assessed the heterogene-
ity in included trials using the I2 statistics. We con-
ducted all statistical analyses using Stata, version
14 (StataCorp, College Station, TX, USA).
Results
Characteristics of included studies
Our electronic search identified 318 potentially rele-
vant citations; of these, we evaluated 10 articles in full
against our inclusion criteria. We excluded three non-
randomized studies, one study that did not report on
women undergoing assisted conception and another
study reporting on the same cohort of women
(Figure 1). We included a total of five trials in our
meta-analysis (n = 843 women).20, 21, 24–26 Two trials
were from Egypt and one was from each of the
United Kingdom, India, and Saudi Arabia. All trials
used 20% IVI solution at the time of embryo transfer
but there were variations in the volume given and the
duration of the protocol. Two trials administered the
first dose of intralipid prior to or at the time of oocyte
retrieval. Four trials administered a second dose of
intralipid following a positive pregnancy test and one
continued intralipid administration fortnightly until
the end of the first trimester. All trials used a normal
saline infusion or no intervention (routine care) as a
comparator (Table 1). All trials included women with
previous implantation failure although the inclusion
threshold varied across included trials. Four trials
excluded women with other known causes for RIF
while one did not report clear exclusion criteria.20
Risk of bias
There was an overall moderate risk of bias of the
included studies with four studies (80%) showing low
risk of bias for randomization and three (60%) for
allocation concealment. Three (60%) studies had low
risk for missing outcome data while two (40%) studies
Citations identified from 
electronic databases
(n = 318)
Full-text articles assessed for 
eligibility
(n = 10)





Non – randomised study design (n = 3)
Did not include conception through IVF 
(n = 1)
Same cohort of patients reported (n = 1)
Studies included 
(n = 5)
FIGURE 1 Selection and
inclusion process of
studies on the effective-
ness of intralipid dur-
ing assisted conception
in women with history
of recurrent implanta-
tion failure
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had high risk of bias for selective outcome reporting
(Figure 2). None of the included studies conducted
appropriate blinding thus raising the risk of
performance bias.
Outcomes
All five trials reported on clinical pregnancy rates and
live births contributing to our meta-analysis. Women
in the IVI group had a higher chance of achieving
clinical pregnancy (172 vs 119, RR 1.55, 95% CI
1.16–2.07, I2 44.2%) and live birth (132 vs 73, RR 1.83,
95% CI 1.42–2.35, I2 0%) post ART treatment com-
pared to no intervention (Figure 3). Only two trials
reported on miscarriage with no clear benefit in the
IVI group (18 vs 30 in Dhakly et al.; 11 vs 10 in Al-
Zebeidi et al.). Similarly, only two trials reported on
biochemical pregnancy (84 vs 76 in Dhakly et al.;
21 vs 8 in Singh et al.); thus, a meta-analysis was not
possible for those two outcomes. One trial reported
two cases of congenital middle ear anomalies in the




Our meta-analysis suggests that compared to routine
care, providing IVI at the time of embryo transfer
could increase the rate of clinical pregnancy and live
birth in women with the history of RIF. The effect
estimates were consistent for both outcomes which
could suggest a persistent benefit through both the
implantation phase and later till the first trimester of
the pregnancy. Such effect could be explained by an
























































































































































































































































































































































































FIGURE 2 Risk of bias in included randomized trials
on the effectiveness of intralipid during assisted con-
ception in women with history of recurrent implanta-
tion failure
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a favorable immunological response to the invading
trophoblast during the implantation phase. None of
the included studies reported serious adverse events
in women receiving IVI. Similar trials in the literature
reported minor side effects such as a flushing feeling,
nausea, and headache.27 Two cases of congenital
abnormalities were reported in one trial of relatively
small sample size. While it is difficult to ascertain cau-
sality due to statistical limitation, we highlight the
importance of reporting fetal anomalies in any future
studies planning to evaluate IVI use pre-pregnancy.
Strength and limitations
We used a prospectively registered protocol and a
standardized methodology to conduct this review.
We assessed the risk of bias in all included studies
and extracted data in duplicate. We contacted two
groups of authors20, 21 to ensure study eligibility for
inclusion. Still, our findings are not without limita-
tions. While all trials used 20% IVI solutions, there
were variations in the used doses, frequency of IVI
administration, and in the ART protocols which could
increase the performance bias. For example, three tri-
als used a diluted form of IVI in normal saline20, 24, 25
while the other two used a concentrated form of IVI
prior to its use.23, 27 Due to the small number of
included studies, we were unable to explore this fur-
ther using a meta-regression. The comparison varied
among included trials (normal saline vs no interven-
tion) with limited information on blinding efforts
(as IVI is of white color). As the reported outcomes
are objective (pregnancy and live births), we perceive
little placebo effect on the quality of reporting,
although performance bias is possible. Finally, we
were unable to investigate the effect of potential effect
modifiers such as the process of ovulation stimula-
tion, the number and quality of transferred embryos
and the use of additional add-on treatments. Such
effect could be best evaluated with individual patient
data meta-analysis; however, given the relatively
small number of women included in this meta-analy-
sis, such an approach is unlikely to yield significant
FIGURE 3 Forest plots of pooled data from studies on the effectiveness of intralipid during assisted conception in women
with history of recurrent implantation failure. (a) Clinical pregnancy and (b) live births
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findings pending the conduct of larger trials in the
future. Our findings are, therefore, important to har-
monize the standardize future trial conduct to yield
more efficient evidence synthesis.
Implications for future practice
The value of several ART add-ons has been heavily
debated with concerns regarding the ethicality of
offering such additional treatments without clear evi-
dence of benefit.28 Our meta-analysis of five random-
ized trials offers a pragmatic overview on the
potential role of IVI to help a specific group of women
affected by RIF. However, given the limitations and
the quality of included trials, we conclude that
adopting the use of IVI in ART practice is at present
immature and offering it a-la-carte to all couples
undergoing ART should not be adopted until larger
RCTs are published with a clear persistent beneficial
effect.
This imprecision in effect size is largely driven by
the variation in treatment protocols and use of IVI
across included studies. There is a need to focus
future research work on evaluating the perceived
immunological effect on IVI on the endometrium at
the implantation phase within larger cohorts of
women with history of recurrent pregnancy loss.
More specifically, there is a need to delineate this per-
ceived impact in both subgroups of RIF and recurrent
pregnancy loss in the first trimester. As the mechanis-
tic effect of IVI on the maternal innate immunological
system remains unclear, there is also a need for more
discovery research to aid the stratification and selec-
tion of women who might benefit the most of IVI.29
Novel tests are now available to aid the identification
of women with nonreceptive endometrium such as
microarray technology which could offer more precise
evaluation of the effectiveness of IVI in future
studies,30 but they remain of limited use in clinical
practice. Several methodological improvements are
required to enhance the quality of future studies on
IVI such as standardizing the definition and manage-
ment pathways for women with RIF3 and following
more transparent reporting using an established core
outcome set for fertility treatments.31
We were unable to evaluate any long-term protec-
tive effect of IVI later on in pregnancy. As it is argued
to promote healthy implantation and placentation, IVI
might reduce the risk of placenta mediated pregnancy
complications (e.g. pre-eclampsia) which are more
common in women undergoing ART.32 Planned long-
term follow-up of randomized cohort is essential to
precisely evaluate such protective effects and aid
more robust evidence synthesis on ART add-ons.
Despite our meta-analysis results suggesting IVI intra-
lipid increased both clinical pregnancy rate and live
birth, the small number of studies makes it challeng-
ing to draw firm conclusions as to the benefit of
intralipid.
In conclusion, evidence to support the use of IVI at
the time of embryo transfer in women with a history
of RIF is limited; more research is needed before
adopting it in clinical practice.
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